Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease therapies, announced participation in the H.C. Wainwright 3rd Annual Kidney Virtual Conference. CEO Shalabh Gupta, M.D. will engage in a Fireside Chat on July 15, 2024, at 2:00 p.m. ET. The event will be accessible live and as an archived webcast for three months on Unicycive's website under the Investors section: Events and Presentations.

News Market Reaction – UNCY

-1.21%

-1.21% Session move

In the trading session that priced this news, UNCY declined 1.21%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024 at 2:00 p.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When will Unicycive Therapeutics participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

Unicycive Therapeutics will participate in the conference on July 15, 2024, at 2:00 p.m. ET.

Who will represent Unicycive Therapeutics at the H.C. Wainwright 3rd Annual Kidney Virtual Conference?

CEO Shalabh Gupta, M.D. will represent Unicycive Therapeutics.

How can I access the webcast of Unicycive Therapeutics' Fireside Chat at the H.C. Wainwright Conference?

The webcast will be available live and archived on Unicycive's website under the Investors section: Events and Presentations.

How long will the archived webcast of Unicycive Therapeutics' Fireside Chat be available?

The archived webcast will be available for three months.

What is the stock symbol for Unicycive Therapeutics?

The stock symbol for Unicycive Therapeutics is UNCY.